Effectiveness of safety warnings in atypical antipsychotic drugs: An interrupted time-series analysis in Spain

Drug Safety

Volumn 32, Issue 11, 2009, Pages 1075-1087

  Sanfélix Gimeno, Gabriel ^a   Cervera Casino, Pedro ^b   Peiró, Salvador ^a   López Valcarcel, Beatriz González ^c   Blázquez, Amparo ^d   Barbera, Teresa ^e  

^a Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^b Departamento de Salud 10   (Spain)

^c UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e Direccián General de Farmacia y Productos Sanitarios   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEMENTIA; DRUG FORMULATION; DRUG SAFETY; DRUG USE; ELDERLY CARE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; SPAIN; TIME SERIES ANALYSIS;

AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG AND NARCOTIC CONTROL; HUMANS; INFORMATION DISSEMINATION; PHYSICIAN'S PRACTICE PATTERNS; RISPERIDONE; SPAIN;

EID: 70349974907     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11316520-000000000-00000     Document Type: Article

References (52)

1. Trontell A. Expecting the unexpected: drug safety, pharma-covigilance and the prepared mind. N Engl J Med 2004; 351: 1385-1387
2. Brewer T, Colditz GA. Postmarketing surveillance and ad-verse drug reactions: current perspectives and future needs. JAMA 1999; 281: 824-829
3. Seligman PJ. "Dear Doctory": evaluating the impact of risk communication efforts. Pharmacoepidemiol Drug Saf 2003; 12: 291-293
4. Campbell WH, Califf RM. Improving communication of drug risks to prevent patient injury: proceedings of a workshop. Pharmacoepidemiol Drug Saf 2003; 12: 183-194
5. Goldman SA. Communication of medical product risk: how effective is effective enough? Drug Saf 2004; 27: 519-534
6. Mazor KM, Andrade SE, Auger J, et al. Communicating safety information to physicians: an examination of dear doctor letters. Pharmacoepidemiol Drug Saf 2005; 14: 869-875
7. Woosley RL. Drug labeling revisions: guaranteed to fail? JAMA 2000; 284: 3047-3049
8. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug pre-scribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006; 15: 369-386
9. Seligman PJ. Thinking outside the (black) box: a new research agenda. Pharmacoepidemiol Drug Saf 2006; 15: 387-389
10. Katz LY. Concerns about health care warnings and their impact on prescribing behaviour. CMAJ 2008; 179: 405-406
11. Comite de Redaccion del Boletin Reacciones Adversas a Medicamentos. La comunicacion de riesgos a los medicos. Reacciones Adversas a Medicamentos-Boletin Informativo del Centro de Farmacovigilancia de la Comunidad de Madrid 2005; 12: 1-4
12. Peiro S, Cervera-Casino P, Bernal-Delgado E. The value of information and information as a value [in Spanish]. Gac Sanit 2006; 20: 168-170
13. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309
14. Biglan A, Ary D, Wagenaar AC. The value of interrupted time-series experiments for community intervention and policy research. Prev Sci 2000; 1: 31-49
15. ATC index with DDDs. January 2002. Oslo: WHO Colla-borating Centre for Drug Statistics Methodology, 2002
16. WHO Collaborating Centre for Drug Statistics Methodo-logy. ATC/DDD index 2009: N05AX08 [online]. Available from URL http://www.whocc.no/atcddd/ indexdatabase/ index.php?query=N05AX08 [Accessed 2009 Jun 30]
17. WHO Collaborating Centre for Drug Statistics Methodo-logy. ATC/DDD index 2009: N05AH03 [online]. Available from URL http://www.whocc.no/atcddd/ indexdatabase/ index.php?query=N05AH03 [Accessed 2009 Jun 30]
18. Box GEP, Jenkins GM. Time-series analysis: forecasting and control. San Francisco (CA): Holden Day, 1976
19. Gomez V, Maravall A. Programs TRAMO (Time Series Regression with ARIMA Noise, Missing Observations and Outliers) and SEATS (Signal Extraction in ARIMA Time Series). Instructions for user. Working Paper 962. Madrid: Servicio de Estudios, Banco de Espana, 1996
20. Girona-Brumos L, Ribera-Montana R, Juarez-Gimenez JC, et al. Positive and negative aspects of pharmaceutical services in Spain: about antidepressants and antipsychotics [in Spanish]. Gac Sanit 2006; 20 Suppl. 1: 143-153
21. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of reg-ulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008; 179: 438-446
22. Peiro S. Complexities in the evaluation of complex inter-ventions [in Spanish]. Gac Sanit 2005; 19: 234-237
23. Galeote M. Failed evaluation of two educative interventions on coxibs prescription in one healthcare area [in Spanish]. Gac Sanit 2005; 19: 489-491
24. Peiro S, Cervera P, Bernal-Delgado E. Selective serotonin reuptake inhibitors in childhood depression: a soap opera that reflects serious problems of drug safety [in Spanish]. Gac Sanit 2005; 19 (5): 401-406
25. Murray ML, Thompson M, Santosh PJ, et al. Effects of the Committee on Safety of Medicines advice on anti-depressant prescribing to children and adolescents in the UK. Drug Saf 2005; 28: 1151-1157
26. Kurian BT, Ray WA, Arbogast PG, et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med 2007; 161: 690-696
27. Libby AM, Brent DA, Morrato EH, et al. Decline in treat-ment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164: 884-891
28. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64: 466-472
29. Dean AJ, Hendy A, McGuire T. Antidepressants in children and adolescents: changes in utilisation after safety warnings. Pharmacoepidemiol Drug Saf 2007; 16: 1048-1053
30. Kurdyak PA, Juurlink DN, Mamdani MM. The effect of antidepressant warnings on prescribing trends in Ontario, Canada. Am J Public Health 2007; 97: 750-754
31. Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65: 94-101
32. Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults [published erratum appears in CMAJ 2008; 178: 1466]. CMAJ 2008; 178: 1005-1011
33. Burkhart GA, Sevka MJ, Temple R, et al. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther 1997; 61: 93-96
34. Thompson D, Oster G. Use of terfenadine and contra-indicated drugs. JAMA 1996; 275: 1339-1341
35. Jacoby JL, Fulton J, Cesta M, et al. After the black box warning: dramatic changes in ED use of droperidol. Am J Emerg Med 2005; 23: 196
36. Habib AS, Gan TJ. The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia. J Clin Anesth 2008; 20: 35-39
37. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000; 284: 3036-3039
38. Raschetti R, Maggini M, Da Cas R, et al. Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 2001; 285: 1840-1841
39. Jones JK, Fife D, Curkendall S, et al. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001; 286: 1607-1609
40. Staniscia T, Romano F, Festi D, et al. Co-dispensing of contraindicated medications in patients using cisapride in Italy. Pharmacoepidemiol Drug Saf 2006; 15: 469-476
41. Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ?Dear Doctor? letters. Pharma-coepidemiol Drug Saf 2001; 10: 211-218
42. Weatherby LB, Nordstrom BL, Fife D, et al. The impact of wording in "Dear doctor" letters and in black box labels. Clin Pharmacol Ther 2002; 72: 735-742
43. Guo JJ, Curkendall S, Jones JK, et al. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12: 295-301
44. Wilkinson JJ, Force RW, Cady PS. Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy 2004; 24: 978-986
45. De Bruin ML, Panneman MJ, Leufkens HG, et al. Use of cisapride with contraindicated drugs in The Netherlands. Ann Pharmacother 2002; 36: 338-343
46. De la Porte M, Reith D, Tilyard M. Impact of safety alerts upon prescribing of cisapride to children in New Zealand. N Z Med J 2002; 115: U24
47. Soumerai SB, Avorn J, Gortmaker S, et al. Effect of gov-ernment and commercial warnings on reducing prescription misuse: the case of propoxyphene. Am J Public Health 1987; 77: 1518-1523
48. Shatin D, Gardner JS, Stergachis A, et al. Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf 2005; 14: 149-154
49. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-833
50. Cluxton RJ, Li Z, Heaton PC, et al. Impact of regulatory labelling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio Medicaid program. Pharmacoepidemiol Drug Saf 2005; 14: 1-9
51. Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008; 14: 523-531
52. Caro I, Ribera R, Pascual B, et al. Utilizacion de farmacos antipsicoticos en pacientes geriatricos. XLVI Congreso de la Sociedad Espanola de Geriatria y Gerontologia; 2004 Jun 9-12; Las Palmas de Gran Canaria